An Official Website of the United States Government
XRpro Technology for the Detection and Evaluation of Carcinogens
- Small Business Information
-
Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
- Phase 1
-
Fiscal Year: 2010Title: XRpro Technology for the Detection and Evaluation of CarcinogensAgency: HHSContract: 1R43CA150404-01Award Amount: $200,000.00
Abstract:
DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. In Phase I, Caldera will demonstrate the feasibility of using its novel XRpro(R) technology to extract, concentrate, quantify, and characterize carcinogens from biological samples. This will also identify protein adduct biomarkers that are involved in critical carcinogenic and biotransformation pathways. This project addresses challenges listed in PA-09-187, including the measure ment of carcinogens directly, without antibodies, dyes, tags, or radioactive materials. PUBLIC HEALTH RELEVANCE: Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. This project addresses challenges listed in PA-09-187, including the measurement of carcinogens directly, without antibodies, dyes, tags, or radioactive materials.Small Business Information at Submission:CALDERA PHARMACEUTICALS, INC.
278 DP Road Suite D LOS ALAMOS, NM 87544EIN/Tax ID: 120098206DUNS: N/ANumber of Employees: N/AWoman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: 95907 |
Program Year/Program: 2010 / SBIR |
|
Agency Tracking Number: CA150404 |
Solicitation Year: N/A |
Solicitation Topic Code: NCI |
Solicitation Number: N/A |